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Introduction: For sulcus superior tumors and central cT4 tumors,
low resectability and poor long-term survival rates are obtained with
single-modality treatment.
Methods: Analysis of all consecutive patients in our prospective
database, who had potentially resectable superior sulcus (cT3–T4)
and central cT4 tumors and were treated with induction chemora-
diotherapy (two courses of cisplatin-etoposide) and concomitant
radiotherapy (45 Gy/1.8 Gy) after multidisciplinary discussion.
Surgery with attempted complete resection was performed in pa-
tients showing response or stable disease on computed tomography.
Results: Between April 2002 and February 2008, 32 consecutive
patients were enrolled. Two patients did not complete the induction
chemoradiotherapy. Thirty patients were reassessed after induction,
28 had response or stable disease by conventional imaging. Twenty-
seven patients were surgically explored since one patient became
medically inoperable during induction treatment. The overall com-
plete resectability was 78% (25/32). Resection was microscopically
incomplete (R1) in two patients. In 11 patients (41%), a pneumo-
nectomy was performed, and in 14 patients (52%), a chest wall
resection was necessary. In 74% of the resected patients, there was
a complete pathologic response or minimal residual microscopic
disease. The mean postoperative hospital stay was 9.2 days with no
hospital mortality and no bronchopleural fistula. With a median
follow-up of 26.5 months, 5-year survival rates are 74% in the
intent-to-treat population (n  32) and 77% in completely resected
patients (n 25), with no statistically significant difference between
sulcus superior tumors and centrally located T4 tumors.
Conclusion: In patients with sulcus superior tumors and in selected
patients with centrally located T4 tumors, trimodality treatment is
feasible with acceptable morbidity and mortality. The complete
resectability is high, and long-term survival is promising.
Key Words: Lung cancer, Superior sulcus, T4, Trimodality treat-
ment, induction therapy.
(J Thorac Oncol. 2009;4: 62–68)
Tumors of the superior sulcus and central T4 tumors are anuncommon subset of non-small cell lung cancer
(NSCLC). If surgery is performed, a major problem is to
obtain a complete resection with clear margins. In superior
sulcus tumors, there is the proximity of critical structures,
such as the spine, brachial plexus, and subclavian artery.
These structures are difficult to approach technically and they
limit the extent of resection. Shaw et al.1 and Paulson2
showed that preoperative radiotherapy resulted in a higher
complete resectability rate. Nevertheless, complete resection
was achieved in only 60% of the patients, and the overall
5-year survival remained 30%.3 Primary surgery for centrally
located T4 tumors disease is unrewarding. A Japanese study
showed that complete resection was possible in only one third
of the patients, with a hospital mortality as high as the
predicted 5-year survival (13%).4
Based on the improved results of induction chemora-
diotherapy followed by surgery for superior sulcus tumors5
and stage III disease,6,7 we started trimodality treatment for
sulcus superior and central T4 tumors in 2002. The aim of
this study was to analyze our results with trimodality treat-
ment in these patients.
PATIENTS AND METHODS
We analyzed the results in our prospective database of all
consecutive patients treated in our hospital with pathologic
proven superior sulcus tumor and centrally located clinical T4
tumors between April 2002 and February 2008. Sulcus superior
tumors were defined as tumors located at the top of the lung with
involvement of the apical chest wall above the level of the
second rib.8 Patients with central tumors had a clinical T4 status
(cT4N0–N1) based on their central location, not on satellite
nodules, malignant pleural effusion, or carinal involvement.
Particular attention was given in patients with superior sulcus
tumors to verify the pretreatment T-status, making certain that
tumors were coded as T4 only if imaging studies clearly docu-
mented spine or subclavian vessel invasion or in case of Horner
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syndrome. In centrally located T4 tumors, clinical staging of the
T-factor was based on computed tomography (CT) or magnetic
resonance imaging (MRI).
Eligibility criteria included a World Health Organiza-
tion performance status of 0–1, age 75 years, and a pre-
dicted forced expiratory volume in 1 second higher than 40%.
Patients had to be able to tolerate cisplatin-based chemother-
apy. Patients were excluded if they were not potential surgi-
cal candidates on medical grounds. All patients were fully
informed about the nature and the purpose of the present
study by a pulmonologist/thoracic surgeon and gave informed
consent before the start of the treatment. This procedure in
general, as well as the analysis of the cohort of this article,
was approved by the institutional review board.
All patients were carefully screened for distant metas-
tasis. In short, this consisted of a thorough clinical examina-
tion and history, blood tests, including a complete blood
count, serum calcium, and liver function tests. All patients
had a contrast-enhanced CT-scan of the thorax and upper
abdomen. Bone scintigraphy was carried out in patients with
bone pain, raised alkaline phosphatase, or serum calcium,
completed by bone radiographs, bone CT, or bone MRI in
case of equivocal findings. Positron emission tomography
(PET) or PET-CT scan was routinely performed in these
patients. Cervical mediastinoscopy was recommended to ex-
clude mediastinal nodal metastasis. The treatment strategy
was decided at the weekly institutional lung cancer multidis-
ciplinary meeting.
The chemotherapy and radiotherapy were administered
concurrently. Chemotherapy consisted of cisplatin 60 mg/m2
on day 1 and day 21, etoposide 120 mg/m2 on days 1–3 and
days 21–23, both administered intravenously in a 3-week
schedule. The total dose of radiation was 45 Gy in fractions
of 1.8 Gy in 25 days (5 weeks), starting on day 1 of the first
chemotherapy cycle. The radiation target (gross tumor vol-
ume, GTV) was defined by CT scan, correlated with PET
scan, either visually either on integrated PET-CT. It included
the primary tumor and in case of uncertainty regarding the
hilar status on CT and/or PET scan, the hilar region was also
encompassed within the GTV. The GTV was then enlarged to
the planning target volume using an isotropic margin of 1.5
cm. All treatments were planned and delivered with 3D-
conformal radiotherapy, according to international accepted
guidelines.9 As the primary aim of this analysis was to look
at the results and major complications when using a trimo-
dality approach for NSCLC with borderline T-factor resect-
ability, we did not make a detailed coding of cisplatin-
etoposide and radiotherapy, as ample information on this is
available. We only registered major safety issues.
Two to 4 weeks after completion of the induction
chemoradiotherapy, each case was re-evaluated to determine
clinical response according to RECIST criteria10 and resect-
ability. Re-evaluation included full pulmonary function tests
(including diffusion capacity) and CT-scan of chest and upper
abdomen. In absence of disease progression (i.e., stable
disease or partial complete response [CR]) patients were
referred for surgery. Patients found to have progressive dis-
ease had other treatment and continued follow-up.
Thoracotomy was undertaken 2 to 4 weeks after com-
pletion of the chemoradiotherapy. All surgical procedures
were performed by the same team, consisting of anatomic
pulmonary resection and systematic nodal dissection.11 The
approach was a posterolateral thoracotomy in case of central
or superior sulcus tumors, a transmanubrial approach12 in
case of an anterior located superior sulcus tumor. Multiple
frozen section examinations were used to determine the
extent of resection and to evaluate its completeness. For
central tumors, the bronchial stump was routinely covered
with an intercostal muscle flap. In case of resection of
superior sulcus tumors, a pleural flap was used to cover the
bronchial stump.
In case of resection, two adjuvant courses of cisplatin
and etoposide were administered. In case of incomplete
resection, radiotherapy boost was considered.
Final pathology response was divided into three cate-
gories: pathologic CR (no residual microscopic tumor), min-
imal microscopic residual (few scattered foci within mostly
necrotic or fibrotic mass), or gross residual tumor (mostly or
entirely viable tumor).5
Survival was reported on an intent to treat basis and
was defined as time from diagnosis till death or last contact
for surviving patients. Survival was calculated according to
the Kaplan-Meier method, with difference between groups
expressed by the log-rank test.
RESULTS
There were 32 patients with superior sulcus tumors or
centrally located T4 tumors planned for this trimodality
approach between April 2002 and February 2008. There were
15 patients with superior sulcus tumors, 17 patients had
centrally located T4 disease. Table 1 shows the characteris-
tics of these 32 patients. Most patients were men, and squa-
mous cell carcinoma (59%) was the predominant histologic
subtype. Two third of superior sulcus tumors were staged as
clinical T4 tumors. For centrally located T4 tumors, the list of
infiltrated organ is reported in Table 1. Most patients were
clinically T4 due to invasion of pulmonary artery (n  5) or
left atrium (n  5).
The treatment scheme of these patients is shown in Figure
1. In all patients with centrally located T4 tumors and in most
patients with superior sulcus tumors (73.3%), cervical medias-
tinoscopy was performed. In four patients with superior sulcus
tumors, no mediastinoscopy was performed because both PET
and CT-scan were negative on mediastinal nodes.
Two patients were planned to start trimodality treat-
ment, but did not initiate induction chemoradiotherapy. One
patient with superior sulcus tumor developed contralateral
pneumonia after invasive surgical staging and was no longer
suitable for multimodality therapy. Another patient with cen-
trally located T4 tumor had rapid disease progression with
occurrence of malignant pleural effusion and central necrosis
of the tumor. This patient received palliative chemotherapy
and needed a palliative pneumonectomy for controlling ne-
crosis and infection a few weeks later. This resection was
incomplete with positive section margins on the left atrium.
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The induction therapy was completed as planned in 30
patients (93.7%). Significant acute toxicity was infrequent. In
total, one patient experienced pneumonia, five patients expe-
rienced neutropenia (febrile neutropenia: two), and two pa-
tients experienced radiation oesophagitis. Three patients
needed hospital admission, one for intravenous antibiotics
(pneumonia) and two for parenteral nutrition.
Re-evaluation showed disease progression in two pa-
tients. Thirteen patients had partial response, and 15 patients
had stable disease on imaging and were scheduled for sur-
gery. Functional re-evaluation after induction chemoradio-
therapy showed that one patient was not fit enough to undergo
surgical resection. This patient was treated by additional
radiotherapy.
Twenty-seven patients (84.4%) underwent surgical explo-
ration. The mean time interval between completion of chemo-
radiotherapy and the surgical intervention was 26 days (range:
16–42 days). Data on the resections performed are summarized
in Table 2. In 25 patients, a complete resection was achieved.
The intent to treat complete resectability rate was 78.1% for
those who underwent surgical exploration it was 92.6%. In two
patients, the resection was microscopically incomplete. Both
patients had pretreatment a T4 superior sulcus tumors and had
microscopic positive margins on the vertebral body.
A pneumonectomy was necessary in 11 patients (right-
sided in six). Most of the pneumonectomies were extended
resection (intrapericardial or combined with chest wall resec-
tion). In 16 patients the resection was confined to lobectomy/
bilobectomy. Sleeve resection was performed in two patients.
As can be expected, in many patients pulmonary resection
with en bloc chest wall resection was performed (n  14).
When the defect was posteriorly located and when there was
no risk of entrapment of the scapula, we did not routinely
reconstruct the chest wall. Chest wall reconstruction with
Gore-Tex 2-mm dual mesh was performed in four patients.
The surgical procedures as shown in Table 2 reflect the extent
of the disease before the induction chemoradiotherapy. The
liberal use of multiple frozen sections could reduce the need
FIGURE 1. Flow diagram showing treatment
scheme in 32 patients with centrally T4 tumors or
superior sulcus tumors.
TABLE 1. Characteristics of All Eligible Patients (n  32)
Age (yrs)
Mean (range) 59.5 (47–74)
Sex
Male 24
Female 8
Side
Right 15
Left 17
Histology
Squamous cell carcinoma 19
Large cell undifferentiated 8
Adenocarcinoma 5
Superior sulcus tumors 15
cT3 5
cT4 10
Spine: 3, plexus: 4, subclavian artery: 3, Horner: 1
Centrally located T4 17
Pulmonary artery 5
Atrium 5
Aorta 3
Extensive mediastinal infiltration 2
Recurrent laryngeal nerve 1
Subclavian artery 1
Clinical N staging (after invasive staging)
N0 30
N1 2
N2 0
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for pneumonectomy and proved to be crucial to avoid unnec-
essary resection of mediastinal structures that seemed mac-
roscopically involved.
In all cases of resection of centrally located tumors
(n  14), the bronchial stump was covered with an
intercostal muscle flap. After resection of superior sulcus
tumors (n  13), the bronchial stump was covered with a
broad pleural flap.
Final pathology response showed pathologic CR in
three patients, minimal microscopic residual disease in 17
patients, and gross residual tumor in seven patients. In 74% of
resected specimens, no or only minimal microscopic vital
tumor was found. Table 3 shows the correlation between
pathologic and radiologic findings in the 27 patients who
underwent resection. Although 15 patients had stable disease
on CT, two thirds of them proved to have a major pathologic
response with no or only small foci of viable tumor in the
resection specimen.
There were no treatment-related deaths. The mean
hospital stay was 9.1 days (range: 15–16 days). Fourteen
patients (52%) had no postoperative complication. The most
observed complications were atrial arrhythmia (15%) and
pneumonia (11%) (Table 4). One of the patients with pneu-
monia had to be admitted to the intensive care for ventilation.
In these series, we observed no bronchopleural fistulae or
empyema. One patient had a prolonged air leak, one patient
developed paralytic ileus, and three patients with superior
sulcus tumors experienced clearly more than usual post-
thoracotomy pain.
Consolidation Chemotherapy
In 23 operated patients, two additional courses of con-
solidation chemotherapy were given 4 to 6 weeks postoper-
atively. Reasons for not delivering consolidation chemother-
apy were poor general condition (1), renal insufficiency (1),
unexplained fever (1), and incomplete resection that was
treated with additional radiotherapy (1).
Follow-up is complete for all patients. Median fol-
low-up is 26.5 months, median follow-up in patients who are
still alive is 33.5 months. At the time of this report, 6 of the
32 patients have died. The overall median survival is not yet
reached with an intent to treat (n  32) projected 1-year
survival of 93% and a projected 5-year survival of 74% or
77% after complete resection (n  25). We observed a trend
of better survival in superior sulcus tumors compared with
central T4 tumors (Figure 2). The projected 5-year survival in
superior sulcus tumors was 86% and 60% in central T4
tumors (p  0.087).
After resection (n  27), four patients have developed
recurrent disease. In two patients with superior sulcus tumors,
there was a local recurrence; in the two other patients (7.4%),
the brain was the first site of relapse.
TABLE 3. Comparison of Pathological and Radiological
Responses in 27 Patients Who were Resected
Total
Radiological Response
Partial Response Stable Disease
Pathological response
Pathologic complete response 3 2 1
Minimal microscopic residual
disease
17 8 9
Gross residual disease 7 2 5
Total 27 12 15
TABLE 4. Postoperative Complications in 27 Patients
Type No Patients Percent of Patients
Atrial arrhythmia 4 15
Pneumonia 3 (1 admittance to ICU) 11
Intense pain 3 11
Sputum impaction 2 7.4
Prolonged air leak 7 d 1 3.7
Ileus 1 3.7
Of the 27 patients who underwent thoracotomy, 14 (52%) had no complications.
ICU, intensive care unit.
TABLE 2. Surgical Procedures in 27 Patients
Resectability
R0 25 92.6%
R1 2
R2 0
Pneumonectomy 11 40.7%
Right pneumonectomy 6
Standard pneumonectomy 2
Intrapericardial pneumonectomy 4
Intrapericardial pneumonectomy  chest wall 4
Intrapericardial pneumonectomy  left atrium 1
Lobectomy/bilobectomy 16 60.3%
Standard lobectomy 2
Sleeve lobectomy 2
Lobectomy  subclavian artery 2
Lobectomy  chest wall 3
Lobectomy  chest wall  processus transversus 3
Lobectomy  chest wall  T1 nerve root 4
Chest wall resection 14
Chest wall reconstruction 4
No chest wall reconstruction 10
Pathology
Complete response 3 7.2%
Minimal microscopic residual disease 17 62.9%
Gross residual tumor 7 25.9%
pTNM
pT0N0M0 4
pT1N0M0 4
pT2N0M0 7
pT3N0M0 5
pT1N1M0 2
pT2N1M0 1
pT3N1M0 1
pT4N0M0 3
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DISCUSSION
Primary surgery for superior sulcus tumors or tumors
infiltrating by direct extension the mediastinal organs (T4) is
unrewarding, as complete resection is not often obtained and
5-year survival is poor. Results of preoperative radiotherapy
(30–35 Gy) followed by surgery in 225 patients from Me-
morial Sloan-Kettering Cancer Centre published by Rusch et
al.3 showed that a complete resection was achieved in only
64% of T3N0 and 39% of T4N0 superior sulcus tumors. An
older study from the same center evaluated the results of
surgery in NSCLC with direct mediastinal tumor extension
who had pN0 or pN1 disease.13 T3N0 lesion have a more
favorable outcome, but still complete resection rate did not
exceed 66%.13 The complete resectability for T4 lesions was
only 18% with a 5-year survival of 12%.
Theoretically, an induction program of concurrent che-
moradiotherapy seems appropriate for superior sulcus tumors
and centrally located T4 tumors. Major problems are often a
large, locally infiltrative tumor and the frequent occurrence of
distant metastasis. Although superior sulcus tumors and cen-
tral T4 disease differ in surgical approach and might differ in
nodal status, both have in common that a complete resection
with clear margins is difficult to obtain because of the
proximity of vital structures.
In February 2002, we started our program of trimodality
treatment in superior sulcus tumors (T3–T4) and centrally lo-
cated T4 tumors. Overall, we obtained a complete resectability
of 78% and an overall 5-year survival of 74%. We observed
similar survival in superior sulcus tumors and centrally T4
tumors although there was a trend of better survival in superior
sulcus tumors. Nevertheless, as shown at the bottom of Figure 2,
the sample size becomes small when analyzing the subset of
superior sulcus tumors and centrally T4 tumors and one should
be careful to draw final conclusions.
Our results are very similar compared with the litera-
ture, although we realize that our duration of follow-up is
rather short to have a solid view beyond 3 years (Table 5). A
North American multicenter study enrolled 110 patients with
mediastinoscopy negative T3-4N0-1 superior sulcus tumors.
The overall complete resectability was 76%. Treatment-re-
lated mortality was 4.5%. Pathologic CR or minimally mi-
croscopic disease was seen in 61 (56%) of resected speci-
mens. Overall 5-year survival was 44% with a 54% after
complete resection.14 Similar results in superior sulcus tu-
mors were reported by the Japan Clinical Oncology Group
with a complete resectability of 68% and an overall 5-year
survival of 56%15 and by the Essen Group with a complete
resectability of 87% and an overall 5-year survival of 46%.16
There are only limited data in the literature of the effect of
trimodality treatment in centrally located T4 disease. The largest
study was published by Rendina et al.17 They performed a
prospective, single institution study of induction chemotherapy
in patients with centrally located, unresectable T4 NSCLC. The
complete resectability rate was 63%, and a 5-year survival of
20% was reported. In a subgroup of patients with T4N0, 4-year
survival was 58%.17 Another study evaluated trimodality treat-
ment in 42 patients with stage III disease treated with trimodality
treatment.18 A small subgroup of patients with T4N0 disease
(eight patients) had an excellent outcome. Eighty-eight percent
of these patients underwent resection. The median survival for
FIGURE 2. Overall survival in cT4 tumors (n  17) com-
pared with sulcus superior tumors (n  15).
TABLE 5. Patient Characteristics and Outcome after Induction Therapy for Superior Sulcus and Central T4 Tumors
Study n
Patient Characteristics Outcome
Superior
Sulcus
Central
T4 (%) Induction Therapy
Radiographic SD
or Response (%)
Surgery
(%)
Operative
Mortality
(%)
R0
Resection
(%)
Survival
cT3
(%)
cT4
(%)
5 yrs
Overall (%)
5 yrs R0
Resection (%)
Rendina et al.17 57 0 0 100 Ch NR 73.8 2.3 63 NR 4 yrs: 30.4%
4 yrs (pN0): 58%
Kwong et al.27a 37 86.5 13.5 0 Ch  RT (60 Gy) 100 100 2.7 97 50 NR
Rush et al.14 110 71 29 0 Ch  RT (45 Gy) 86 80 2.3 76 46 54
Kunitoh et al.15 76 74 26 0 Ch  RT (45 Gy) 86.8 76 3.5 68 56 70
Marra et al.16 31 81 19 0 CH CH  RTb 100 94 6.4 87 46 NR
Present series 32 15.6 31.2 53.1 Ch  RT (45 Gy) 87 84.4 0 78 74 77
a cN2: 9; cN3: 1; cM1: 5.
b Hyperfractionated radiotherapy.
R0, completely resected patients; NR, not reported; RT, radiotherapy; Ch, chemotherapy.
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this (small) subgroup was 51 months. Two consecutive
Southwest Oncology Group (SWOG) trials, including pa-
tients with stage IIIB showed in the subgroup of T4N0 –N1
a 6-year survival of 49% in the group treated with trimo-
dality treatment (SWOG 8805) versus a 5-year survival of
17% in a group of T4N0 tumors treated with chemoradio-
therapy alone (SWOG 9019).6,19
Many patients with T4 disease also have mediastinal
lymph node involvement. These patients have a dismal prog-
nosis with trimodality treatment.17 The negative predictive
value of PET scan is much lower in this group of patients
because it is often impossible to discriminate on PET scan
tumor from adjacent mediastinal nodes.20 Therefore, invasive
mediastinal staging should be performed regardless of the
finding on CT or PET-scan.21 In our study, all patients with
centrally located T4 tumors underwent cervical mediastinos-
copy. At the onset of this study, we performed also in all
patients with superior sulcus tumors invasive surgical stag-
ing. Because we never had positive mediastinal nodes when
both CT and PET were negative in this subgroup of patients
and because discrimination of tumor from mediastinal nodes
is often possible in small posteriorly located superior sulcus
tumors, we did not continue to perform routinely cervical
mediastinoscopy in this group of patients.
Operative morbidity and mortality are a major concern
after surgery and induction chemoradiotherapy. Several stud-
ies have shown a high mortality in this setting, mainly after
right pneumonectomy.22–24 In our study there was no treat-
ment-related mortality, and morbidity was minimal with no
bronchopleural fistula or empyema. We included patients
with World Health Organization performance status 0–1
younger than 75 years old. Fluid restriction and coverage of
the bronchial stump (with intercostal muscle after pneumo-
nectomy or sleeve lobectomy) were routinely performed to
avoid adult respiratory distress syndrome and bronchopleural
fistula. A study from Eberhardt et al25 evaluated trimodality
treatment in 94 patients with stage IIIA-IIIB disease. Postop-
erative mortality was 7%, the main reason was bronchopleu-
ral fistula. Since the routing coverage of stump with intercos-
tal muscle, no severe complication has occurred. We
modified the coverage of the bronchial stump according to the
operative procedure. In patients with centrally located T4
tumors, there is a high chance of pneumonectomy, and
pneumonectomy is more at risk for bronchial wound dehis-
cence. In patients with superior sulcus tumors most resections
can be performed with lobectomy. Moreover, due to the
posterior chest wall resection in most of the patients with
superior sulcus tumors, an intercostal muscle flap cannot
easily be used. In these patients, the bronchial stump was
covered with a broad pleural flap.
Furthermore, the liberal use of frozen sections proved
to be helpful to reduce the extent of resection of vital
mediastinal structures. Some superior sulcus tumors are small
and could technically be resected by wedge resection. In all
patients, we performed an anatomic resection. In patients
with superior sulcus tumors, a survival benefit was shown
with a 5-year survival after lobectomy of 60% compared with
33% after limited resection. After lobectomy, there was also
reduction in local recurrence.26
In our study, in 74% of resected specimens no or only
minimal microscopic vital tumor was found. Long-term re-
sults of SWOG trial 9416 showed, however, that minimal
microscopic residual disease was not predictive of outcome,
this in contrast to outcome of patients with pathologic CR
who had a statistically significant better survival.14
The concurrent chemoradiotherapy scheme with cispla-
tin-etoposide and radiotherapy (45 Gy) have shown to be
effective and safe in trimodality treatment.7,14 Newer drugs or
increasing the dose of radiation may be more effective but
also more toxic. In our study, treatment morbidity was min-
imal with no mortality and only two patients experienced
local recurrence (7.4%). Some centers have either used hy-
perfractionation or added higher dose three-dimensional ra-
diation with doses varying from 50 to 70 Gy.16,27 Complete
resection was as high as 97.3% with an operative mortality of
2.7%. The overall median survival time was 2.6 years.27
The most common site of metastasis was the brain,
which accounted for half of all recurrences in our series and
affected 7% of patients. In the Intergroup study, up to 40% of
patients had brain metastasis as the only site of recurrence.14
There is evidence from nonrandomized studies in locally
advanced NSCLC that prophylactic pancranial irradiation
(PCI) reduces recurrence in the brain and improved surviv-
al.28 Because sulcus superior tumors and centrally located T4
tumors are relatively rare, it is not feasible to perform a
randomized PCI trial in this subset of patients. Given the fact
that many patients develop brain metastasis as the only site of
recurrence, PCI should be considered in patients who had a
complete resection after induction chemoradiotherapy.
In our study, clinical T staging was mainly based on CT
or MRI imaging techniques. We are aware that this can be
subject to a potential margin of error. All these patients were
discussed at the multidisciplinary oncological meeting in the
presence of an experienced chest radiologist and nuclear
physician. Studies have shown that in experienced hands, CT
can be often accepted for the diagnosis of central T4 tu-
mors.17 A possible way to discriminate between cT3 and cT4
might be thoracoscopy that was used in 20 of 57 patients in
the study of Rendina et al. or alternatively pericardios-
copy.17,29 Nevertheless, since it is impossible by thoracos-
copy to directly palpate the tissues, it is often difficult to
differentiate between real T3 and T4 lesion. Moreover, there
is a risk of tumor spread during dissection of the lung and the
mediastinal organs.
Our study results give further support to recent pub-
lished guidelines of the American College of Chest Physi-
cians.21 In patients with potentially resectable, nonmetastatic
sulcus superior tumor, preoperative concurrent chemoradio-
therapy before resection is recommended (grade IB). At the
present time, there are no guidelines for T4N0–N1 disease. It
is unlikely to have a prospective phase 3 study testing the role
of surgery in this uncommon subset of patients. Based on our
results and other published data, it seems appropriate to
propose trimodality treatment to selected fit patients with
T4N0–N1 disease.
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